Altimmune Accounts Payable vs Short Long Term Debt Total Analysis

ALT Stock  USD 8.25  0.07  0.86%   
Altimmune financial indicator trend analysis is way more than just evaluating Altimmune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altimmune is a good investment. Please check the relationship between Altimmune Accounts Payable and its Short Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Accounts Payable vs Short Long Term Debt Total

Accounts Payable vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altimmune Accounts Payable account and Short Long Term Debt Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Altimmune's Accounts Payable and Short Long Term Debt Total is -0.32. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Altimmune, assuming nothing else is changed. The correlation between historical values of Altimmune's Accounts Payable and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Altimmune are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Accounts Payable i.e., Altimmune's Accounts Payable and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

-0.32
Relationship DirectionNegative 
Relationship StrengthInsignificant

Accounts Payable

An accounting item on the balance sheet that represents Altimmune obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Altimmune are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Short Long Term Debt Total

Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.02).
 2021 2022 2023 2024 (projected)
Research Development74.5M70.5M65.8M69.1M
Depreciation And Amortization551.3K500K477K435.7K

Altimmune fundamental ratios Correlations

0.40.430.85-0.94-0.420.460.940.980.080.780.370.650.450.990.20.19-0.120.02-0.25-0.240.050.010.470.180.81
0.41.0-0.14-0.440.3-0.010.430.450.39-0.12-0.08-0.261.00.420.35-0.11-0.1-0.290.24-0.12-0.22-0.190.93-0.290.37
0.431.0-0.11-0.480.270.030.470.480.41-0.09-0.03-0.221.00.450.36-0.06-0.12-0.310.25-0.13-0.23-0.20.94-0.30.36
0.85-0.14-0.11-0.75-0.640.490.760.8-0.150.910.420.85-0.090.830.010.26-0.050.19-0.42-0.180.20.1-0.040.350.68
-0.94-0.44-0.48-0.750.48-0.49-1.0-0.95-0.25-0.75-0.55-0.64-0.48-0.94-0.35-0.420.250.250.140.370.120.1-0.55-0.04-0.62
-0.420.30.27-0.640.48-0.67-0.5-0.5-0.3-0.84-0.15-0.940.26-0.45-0.47-0.130.430.290.030.550.310.330.280.07-0.31
0.46-0.010.030.49-0.49-0.670.490.490.260.630.160.640.030.470.40.18-0.27-0.220.18-0.32-0.22-0.150.15-0.090.33
0.940.430.470.76-1.0-0.50.490.960.250.760.540.660.480.940.340.41-0.26-0.25-0.14-0.38-0.12-0.120.530.040.63
0.980.450.480.8-0.95-0.50.490.960.220.780.340.680.490.980.340.17-0.26-0.16-0.15-0.38-0.1-0.120.490.080.82
0.080.390.41-0.15-0.25-0.30.260.250.22-0.02-0.010.130.40.140.950.06-0.42-0.650.51-0.45-0.61-0.620.31-0.36-0.01
0.78-0.12-0.090.91-0.75-0.840.630.760.78-0.020.330.95-0.070.780.180.22-0.20.0-0.3-0.340.02-0.07-0.030.080.6
0.37-0.08-0.030.42-0.55-0.150.160.540.34-0.010.330.27-0.040.34-0.050.96-0.08-0.18-0.15-0.090.050.170.20.16-0.15
0.65-0.26-0.220.85-0.64-0.940.640.660.680.130.950.27-0.210.660.310.18-0.31-0.11-0.2-0.44-0.12-0.19-0.210.10.5
0.451.01.0-0.09-0.480.260.030.480.490.4-0.07-0.04-0.210.460.35-0.08-0.14-0.290.24-0.15-0.24-0.160.94-0.260.39
0.990.420.450.83-0.94-0.450.470.940.980.140.780.340.660.460.260.18-0.09-0.02-0.2-0.220.07-0.10.470.130.81
0.20.350.360.01-0.35-0.470.40.340.340.950.18-0.050.310.350.260.01-0.42-0.60.43-0.48-0.58-0.630.26-0.360.12
0.19-0.11-0.060.26-0.42-0.130.180.410.170.060.220.960.18-0.080.180.01-0.05-0.240.02-0.040.020.070.170.09-0.35
-0.12-0.1-0.12-0.050.250.43-0.27-0.26-0.26-0.42-0.2-0.08-0.31-0.14-0.09-0.42-0.050.7-0.240.970.93-0.03-0.050.04-0.13
0.02-0.29-0.310.190.250.29-0.22-0.25-0.16-0.650.0-0.18-0.11-0.29-0.02-0.6-0.240.7-0.380.740.740.49-0.270.510.09
-0.250.240.25-0.420.140.030.18-0.14-0.150.51-0.3-0.15-0.20.24-0.20.430.02-0.24-0.38-0.13-0.38-0.480.14-0.01-0.23
-0.24-0.12-0.13-0.180.370.55-0.32-0.38-0.38-0.45-0.34-0.09-0.44-0.15-0.22-0.48-0.040.970.74-0.130.880.08-0.060.16-0.25
0.05-0.22-0.230.20.120.31-0.22-0.12-0.1-0.610.020.05-0.12-0.240.07-0.580.020.930.74-0.380.880.07-0.140.180.05
0.01-0.19-0.20.10.10.33-0.15-0.12-0.12-0.62-0.070.17-0.19-0.16-0.1-0.630.07-0.030.49-0.480.080.07-0.050.48-0.04
0.470.930.94-0.04-0.550.280.150.530.490.31-0.030.2-0.210.940.470.260.17-0.05-0.270.14-0.06-0.14-0.05-0.30.28
0.18-0.29-0.30.35-0.040.07-0.090.040.08-0.360.080.160.1-0.260.13-0.360.090.040.51-0.010.160.180.48-0.30.15
0.810.370.360.68-0.62-0.310.330.630.82-0.010.6-0.150.50.390.810.12-0.35-0.130.09-0.23-0.250.05-0.040.280.15
Click cells to compare fundamentals

Altimmune Account Relationship Matchups

Altimmune fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets54.1M245.1M218.9M206.9M210.6M221.2M
Other Current Liab3.6M11.0M6.1M10.6M9.6M17.0M
Total Current Liabilities3.9M12.0M18.3M17.1M12.1M21.2M
Total Stockholder Equity45.5M225.9M199.1M185.3M194.1M203.8M
Net Debt(7.2M)(114.1M)(188.8M)(110.0M)(134.4M)(127.7M)
Retained Earnings(137.4M)(186.4M)(293.2M)(377.9M)(466.3M)(443.0M)
Accounts Payable18.2K612.3K2.0M4.8M2.1M1.5M
Cash9.0M115.9M190.3M111.1M135.1M141.9M
Cash And Short Term Investments37.2M215.9M190.3M184.9M197.8M207.7M
Common Stock Total Equity876.01.5K3.7K4.1K4.7K3.9K
Common Stock Shares Outstanding13.1M25.6M41.3M46.9M53.2M55.9M
Liabilities And Stockholders Equity54.1M245.1M218.9M206.9M210.6M221.2M
Other Current Assets504.4M2.0B13.4B5.4M7.0M6.6M
Other Stockholder Equity187.9M417.3M497.3M568.4M665.4M698.7M
Total Liab8.5M19.2M19.7M21.6M16.5M27.3M
Total Current Assets39.4M230.3M204.1M192.8M209.6M220.1M
Common Stock1.5K3.7K4.1K5K7K4.2K
Other Assets128.5K977.2K73.8K19K1.00.95
Non Current Liabilities Total4.6M7.2M1.5M4.6M4.4M4.7M
Short Term Debt259.4K356.7K411.5K452K496K471.2K
Short Long Term Debt Total2.1M2.2M1.9M1.1M671K637.5K
Property Plant And Equipment Net1.8M2.0M1.4M1.1M1.0M1.5M
Non Current Assets Total14.7M14.9M14.7M14.1M1.0M963.3K
Non Currrent Assets Other128.5K73.4K872.0K615K100.0K95.0K
Net Receivables1.7M12.4M5.8M2.5M4.9M5.0M
Property Plant And Equipment Gross1.8M2.0M1.4M2.6M2.6M1.6M
Accumulated Other Comprehensive Income(5.0M)(5.0M)(5.0M)(5.2M)(5.0M)(4.8M)
Intangible Assets12.7M12.8M12.4M12.4M14.3M11.8M
Net Tangible Assets32.8M213.1M186.7M172.9M198.8M208.7M
Long Term Debt1.9M1.9M1.8M1.5M1.7M1.5M
Retained Earnings Total Equity(116.9M)(137.4M)(186.4M)(293.2M)(337.1M)(354.0M)
Capital Surpluse170.2M187.9M417.3M497.3M571.9M600.5M
Property Plant Equipment1.1M1.1M1.4M1.7M1.9M2.0M
Long Term Debt Total1.9M1.9M1.8M1.5M1.7M2.0M
Non Current Liabilities Other2.8M5.4M1.5M3.9M4.2M4.4M
Other Liab3.1M7.2M330.5K3.9M4.5M3.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.